Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout

BMC Musculoskeletal Disorders

William J Taylor²  Fiona M McQueen¹  Keith J Petrie³  Anne Horne⁴  Meaghan E House⁴  Nicola Dalbeth⁴ 

[1] Department of Molecular Medicine, University of Auckland, Auckland, 1023, New Zealand;Department of Medicine, University of Otago Wellington, PO Box 7343, Wellington, 6242, New Zealand;Department of Psychological Medicine, University of Auckland, Auckland, 1023, New Zealand;Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Rd, Grafton, Auckland, 1023, New Zealand

关键词: Allopurinol;    Target;    Urate;    Gout;   

Others  :  1145856
DOI  :  10.1186/1471-2474-13-174

 received in 2012-07-27, accepted in 2012-09-12,  发布年份 2012

【 摘 要 】

Background

Long term serum urate (SU) lowering to a target of <0.36 mmol/l (6 mg/dl) is recommended for effective gout management. However, many studies have reported low achievement of SU targets. The aim of this cross-sectional study was to examine the clinical and psychological factors associated with SU targets in patients with gout.

Methods

Patients with gout for <10 years were recruited from primary and secondary care settings. SU target was defined as SU concentration <0.36 mmol/L at the time of the study visit. Both clinical and psychological factors associated with SU target were analysed. The relationship between SU target and measures of gout activity such as flare frequency, tophi, work absences, and Health Assessment Questionnaire-II was also analysed.

Results

Of the 273 patients enrolled into the study, 89 (32.6%) had SU concentration <0.36 mmol/L. Urate-lowering therapy (ULT) use was strongly associated with SU target (p < 0.001). In those patients prescribed ULT (n = 181), allopurinol dose, patient confidence to keep SU under control, female sex, and ethnicity were independently associated with SU target. Other patient psychological measures and health-related behaviours, including adherence scores, were not independently associated with SU target in those taking ULT. Creatinine clearance, diuretic use, age, and body mass index were not associated with SU target. Patients at SU target reported lower gout flare frequency, compared with those not at target (p = 0.03).

Conclusions

ULT prescription and dosing are key modifiable factors associated with achieving SU target. These data support interventions focusing on improved use of ULT to optimise outcomes in patients with gout.

【 授权许可】

   
2012 Dalbeth et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Perez-Ruiz F: Treating to target: a strategy to cure gout. Rheumatology (Oxford) 2009, 48(2):9-14.
• [2]Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001, 28:577-580.
• [3]Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004, 51:321-325.
• [4]Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A: Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356-360.
• [5]Perez-Ruiz F, Martin I, Canteli B: Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007, 34:1888-1893.
• [6]Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007, 46:1372-1374.
• [7]Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
• [8]Dalbeth N, Kumar S, Stamp L, Gow P: Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33:1646-1650.
• [9]Roddy E, Zhang W, Doherty M: Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007, 66:1311-1315.
• [10]Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS: Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009, 11:R46. BioMed Central Full Text
• [11]Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005, 44:1038-1042.
• [12]Edwards NL, Quality of Care in Patients with Gout: Why is Management Suboptimal and What Can Be Done About It?. Curr Rheumatol Rep: Curr Rheumatol Rep; 2010.
• [13]Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA: Patients and providers view gout differently: a qualitative study. Chronic Illn 2010, 6:263-271.
• [14]Solomon DH, Avorn J, Levin R, Brookhart MA: Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008, 67:609-613.
• [15]Suppiah R, Dissanayake A, Dalbeth N: High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors. N Z Med J 2008, 121:43-50.
• [16]Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
• [17]Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, Horne A, Gamble G, McQueen FM, Taylor WJ: Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res (Hoboken) 2011, 63:1605-1612.
• [18]Talbot F, Nouwen A, Gingras J, Gosselin M, Audet J: The assessment of diabetes-related cognitive and social factors: the Multidimensional Diabetes Questionnaire. J Behav Med 1997, 20:291-312.
• [19]Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT: Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011, 63:412-421.
• [20]Spencer K, Carr A, Doherty M: Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 2012.
• [21]Rees F, Jenkins W, Doherty M: Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2012.
• [22]Chandratre P, Roddy E, Mallen C: Patient related factors are also important in treating gout. BMJ 2012, 344:e191.
• [23]Dalbeth N, Lindsay K: The patient's experience of gout: new insights to optimize management. Curr Rheumatol Rep 2012, 14:173-178.
• [24]Reach G: Treatment adherence in patients with gout. Joint Bone Spine 2011, 78:456-459.
• [25]Zhu Y, Pandya BJ, Choi HK: Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011, 63:3136-3141.
• [26]Prior IA, Rose BS, Harvey HP, Davidson F: Hyperuricaemia, gout, and diabetic abnormality in Polynesian people. Lancet 1966, 1:333-338.